Similar to BCORmut AML, loss-of-function of EZH2 is associated with resistance to cytarabine [61]; however, the mechanisms of resistance are complex—driven by apoptosis evasion, increased proliferation, and alteration of transporter function. Here, EZH2 is linked to acute myeloid leukemia.